Back

The cost-effectiveness of sacubitril/valsartan (LCZ696) in the treatment of patients with heart failure with reduced ejection fraction in Norway

27 August 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Pharmacologic approaches in HF: could we do better? Heart failure, other ESC Premium Access ESC Congress 2016

9 More presentations in this session

Presentation thumbnail
The risk of atrial fibrillation with ivabradine treatment: A meta-analysis with trial sequential analysis of over 40000 patients
Associate Professor I. Tanboga (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Differential impacts of digoxin modulated by volume status on one-year mortality in patients with acute heart failure
Doctor W. Wang (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Dosage-dependent association between betablocker therapy with Carvedilol or Metoprolol and the risk of appropriate ICD therapy in primary prevention ICD patients.
Doctor A. Ruwald (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Effect of in-hospital treatment on short-term mortality of elderly versus non-elderly patients hospitalized for acute heart failure
Doctor S. Katsanos (Athens, GR)
Abstract
Presentation thumbnail
Potential clinical application of LCZ696 in patients with chronic heart failure in real life clinical practice: results from TREAT HF Study
Professor Y. Cavusoglu (Eskisehir, TR)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacologic approaches in HF: could we do better?

The Event

Event poster

ESC Congress 2016

27 August - 31 August 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources